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Ethanolic extract of Polygala senega (EEPS) had little or no cytotoxic eﬀects on normal lung cells, but caused cell death and
apoptosis to lung cancer cell line A549. In the present paper, ethanolic root extract of P. senega (EEPS) was nanoencapsulated
(size: 147.7nm) by deploying a biodegradable poly-(lactic-co-glycolic) acid (PLGA). The small size of the NEEPS resulted in
an enhanced cellular entry and greater bioavailability. The growth of cancer cells was inhibited better by NEEPS than EEPS.
Both EEPS and NEEPS induced apoptosis of A549 cells, which was associated with decreased expression of survivin, PCNA
mRNA, and increased expression of caspase-3, p53mRNAs of A549 cells. The results show that the anticancer potential of the
formulation of EEPS-loaded PLGA nanoparticles was more eﬀective than EEPS per se, probably due to more aqueous dispersion
after nanoencapsulation. Therefore, nanoencapsulated ethanolic root extract of P. senega may serve as a potential chemopreventive
agent against lung cancer.
1.Introduction
There are more than 170000 new cases of lung cancer every
year in the United States, which is the leading cause of cancer
death both in the United States [1] and throughout the
world. Many plant extracts show immunopotentiating and
antitumor properties [2, 3]. Ethanolic extract of Polygala
senega is used as an expectorant to treat cough, sore throat,
bronchitis, and asthma [4, 5] and as an antihypoglycemic
agent [6]. The saponins of P. senega are used as vaccine
adjuvants to increase speciﬁc immune responses [7]. P.
senega was tested as anti-inﬂammatory properties on RAW
264.7 macrophage cell lines [8]. P. senega has poor water
solubility that prevents aquatic dispersion making its poten-
tial rather restricted because of its lesser bioavailability.
Therefore, we have examined if suitable nanoencapsulation
of the ethanolic extract could enhance its bioavailability
by enhancing its cellular uptake. In the present paper, we
have encapsulated ethanolic plant extract of P. senega and
then compared the anticancer potentials of both ethanolic
extract of P. senega (EEPS) and the nanoencapsulated form
(NEEPS) against a lung cancer cell line A549. We have
employed the technology used earlier to nanoencapsulate
a homeopathic mother tincture of Gelsemium sempervirens
[9].
In this study, biodegradable nanoparticles made from
Poly (d,l-lactide-co-glycolic acid) (PLGA), which have been
e x t e n s i v e l yu s e da sd r u gd e l i v e r ys y s t e m sf o rav a r i e t y
of drugs [10, 11], were chosen as carriers. Polymeric
nanoparticles show advantages with respect to other drug
delivery systems, such as, more stability during storage [12].
Moreover, these colloidal systems, after intravenous admin-
istration, may extravasate solid tumors, where the capillary
endothelium is defective [13, 14]. In the last two decades,
PLGA has attracted considerable attention and interest due
to its excellent biocompatibility and biodegradability [9,
10]. Current literature is replete with studies investigating
hydrophobic drug incorporation into PLGA nanoparticles
[15, 16]. It is relatively easy to entrap hydrophobic drugs into
PLGA nanoparticles for their hydrophobic nature.
2.Materials
2.1. Source of the Ethanolic Extract of P. senega (EEPS).
EthanolicextractofrootofP. senega isusedasahomeopathic2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: (a) SEM image of nanoparticles of P. senega prepared from PLGA. (b, c) Surface topography of nanoparticles obtained by AFM.
mother tincture. In the present paper, homeopathic mother
tincture of P. senega was procured from Dr. Wilmar Schwabe
India Private Limited, A-36, Sector 60, Noida, India. 100mL
ofthemothertinctureofP. senega (48%ethanol)wasinitially
evaporated using rotary evaporator at 40◦C and dried in
vacuum desiccator. This dried extract of ethyl P. senega
(EEPS) was used for the present experiment.
2.2. Formation of Blank Nanoparticles and Drug-Loaded
Nanoparticles. PLGA nanoparticles formation was per-
formed under optimal conditions by solvent displacement
techniqueofFessietal.[17].Inbrief,ﬁrstaccuratelyweighed
50mg PLGA (purchased from Sigma Chemical Co. St. Louis,
MO, USA) and 10mg of dried drug were dissolved in
3mL acetone. Next, the organic phase mixture was added
dropwise (0.5mL/min) into 20mL aqueous solution con-
taining stabilizer, 1% (polyoxyethylene-polyoxypropylene)
(F68; w/v), and which was then stirred at 400rpm by
a laboratory magnetic stirrer at room temperature until
complete evaporation of the organic solvent took place. The
redundant stabilizer was removed from the nanoparticles by
centrifugation at 25,000g and 4◦C for 30 minutes (REMI C
24 centrifuge, REMI Instruments Limited, India). The pellet
was resuspended in Milli-Q water and washed three times.
The obtained nanoparticles loaded suspensions were stored
at 4◦C until further use.
2.3. Surface Morphology. Scanning electron microscopy
(SEM) was performed to evaluate the surface morphology of
nanoparticles.Nanoparticlessamplesweredriedfor24hours
before the analysis.
2.4. Particle Size Analysis and Zeta Potential Measurements.
Dynamic light scattering (DLS) was used for measurement
of average hydrodynamic diameters and polydispersity index
(Pdi) (Malvern Zetasizer Nano-ZS, Malvern Instruments,
UK). Each sample was analyzed in triplicate at 20◦Ca ta
scattering angle of 173. Pure water was used as a reference
for dispersing medium.
Zeta potential data were collected through electro-
phoretic light scattering at 25◦C, 150V, in triplicate for each
sample (Malvern Zetasizer Nano-ZS, Malvern Instruments,
UK), in pure water. The instrument was calibrated with
Malvern-50V standard before each analysis cycle.
2.5. Characterization by Atomic Force Microscopy. The sur-
face properties of drug loaded nanoparticles were visualized
by an atomic force microscope (Veeco di CP-11) under
normalatmosphericcondition.Exploreratomicforcemicro-
scope was in tapping mode, using high-resonant-frequency
(F0 = 241kHz) pyramidal cantilevers with silicon probes
having force constants of 41N/m. Scan speeds were set at
2Hz. The samples were diluted 10 times with distilled water
and then dropped onto glass slides, followed by vacuum
drying for 24 hours at 25◦C. Height measurements were
obtained using AFM image analysis software.
2.6. Entrapment Eﬃciency (EE, %). The entrapment eﬃ-
ciency (EE, %) of EEPS loaded in PLGA nanoparticles wasEvidence-Based Complementary and Alternative Medicine 3
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Figure 2: (a) Average particle size obtained from DLS data for PLGA-encapsulated nanoparticle. (b) Zeta potential of PLGA-encapsulated
nanoparticle.
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Figure 3: Cell viability of blank nanoparticles, EEPS and NEEPS, with diﬀerent concentrations against in normal lung cells (a) and A549 cell
line (b) by MTT assay. ∗(P<. 05), ∗∗(P<. 01), ∗∗∗(P<. 001). The data represent the means ± SD (n = 3). Values of nanoparticles compared
to its unencapsulated form. All results were expressed with vehicle control as 100%.
determinedasfollows:thenanoparticleswereseparatedfrom
the unentrapped free drug using NANOSEP (100kD cut oﬀ)
membrane ﬁlter and the amount of free drug in the ﬁltrate
was measured using spectrophotometer (SHIMADZU UV-
1700). The EE (%) was calculated by EE (%) = ([Drug]tot
[Drug]free)/[Drug]tot ×100.
2.7. Cell Culture
2.7.1. Reagents. Dulbecco’s modiﬁed Eagle medium
(DMEM),fetalbovineserum(FBS),penicillin,streptomycin,
neomycin (PSN) antibiotic, trypsin, and ethylene diamine
tetra acetic acid (EDTA) were purchased from Gibco BRL
(Grand Island, NY, USA). Tissue culture plastic wares were
obtained from BD Bioscience (USA). All organic solvents
used were of HPLC grade. Propidium iodide, MTT (3-(4,5-
Dimethyl-thiazol-2-yl)-2, S-diphenyltetrazolium bromide),
and all other chemicals used were purchased from Sigma
Chemical Co. (St. Louis, MO, USA).
2.7.2. Cell-Culture Procedure. The A549 cell line obtained
fromNationalCentreforCellScience,Pune,Indiawasgrown
at 37◦C in 5% carbon dioxide atmosphere in Dulbecco’s
modiﬁed Eagle’s Medium (DMEM) supplemented with 10%
fetal bovine serum and 1% antibiotic (PSN). For exper-
imental studies, cells were grown to 80–90% conﬂuence,
harvested with ice-cold buﬀer saline (PBS) and plated at
desired density and allowed to re-equilibrate for 24 hours
before any treatment. Normal lung cells of mice were also
cultured and exposed to both EEPS and NEEPS to test their
cytotoxic eﬀect, if any.
2.8. Treatment of Drug and Placebo (48% Ethanol). Diﬀerent
amounts of EEPS, NEEPS, and blank nanoparticles (PLGA),
namely, 20μg/105 cells, 40μg/105 cells, 80μg/105 cells,
100μg/105 cells, 160μg/105 cells, and 200μg/105 cells were
poured into diﬀerent wells. A well was also provided with
the ethanol placebo (2μl 48%) (“vehicle” of P. senega mother
tincture). After 24 hours of treatment, diﬀerent experiments
were performed.
2.9. Cytotoxicity Determination by the MTT Assay. Viability
of normal lung cells and A549 cells was determined by
MTT assay after treatment of blank nanoparticles, EEPS4 Evidence-Based Complementary and Alternative Medicine
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Figure 4: (a) Cellular uptake of nanoparticles of ethanolic extract of P. senega and its unencapsulated form. A549 cells were incubated
with NEEPS and EEPS at diﬀerent time intervals and the cellular uptake (blue ﬂuorescence) was monitored by ﬂuorescence microscopy. (b)
Percentages of cells exhibiting ﬂuorescence at diﬀerent exposures of EEPS and NEEPS, respectively. ∗(P<. 05), ∗∗(P<. 01), and ∗∗∗(P<
.001). The data were taken from six replicates.
and NEEPS [18]. Brieﬂy, 0.6 × 104 cells/well were seeded
into 96-well microtiter plates. Nanoparticle suspensions,
EEPS and NEEPS, were serially diluted in DMEM/10%
fetal bovine serum from 200μg/mL to 20μg/mL (total of
six concentrations). These diluted materials were separately
incubatedwithA549cellsandnormallungcellsfor24hours.
Triplicate measurements were made for each concentration.
At the end of the treatment, 20μlo f2 m g / m LM T T( 3 ,
5-dimethylthiazol-2-yl)-2, 5-dephenyltetrazolium bromide)
was added to each well, and the plates incubated for 4 hours
at 37◦C. Finally, acidic isopropanol (100μl) was added to
each well, after which optical absorbance at 595 nm was
readonascanningmultiwellspectrophotometerplatereader.
T h ec e l lv i a b i l i t yw a se x p r e s s e da sC e l lv i a b i l i t y= Optical
Density (OD) of drug treated samples/OD of control sample
× 100.
2.10. EEPS Uptake in Cells by Fluorescence Method. The
cellular uptake of EEPS and NEEPS in A549 cells was
analyzed. In brief, cells were washed twice with PBS. The
washed cells were resuspended in media and then incubated
with EEPS and NEEPS for diﬀerent time periods. Cells were
then examined under a ﬂuorescence microscope (Carl Zeiss,
Germany). The percentage of ﬂuorescence positive cells was
measured using a software Motic image, China.
2.11. Apoptosis Analysis through Terminal Transferase dUTP
Nick End Labeling (TUNEL) Assay. The DNA strand breakEvidence-Based Complementary and Alternative Medicine 5
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Figure 5: (a) EEPS and NEEPS induced apoptosis in A549 cells by TUNEL assay. Ten thousand events were collected and analysed for each
sample. (i) A549 cells cultured in DMEM with 10% FBS for 24 hours. (ii)-(iii) Cells treated with two doses of EEPS (100 and 200μg), and
(iv)-(v) Cells treated with two doses of NEEPS (100 and 200μg). The viable cells are located in the lower left corner (negative for both FITC
and PI). Early apoptotic cells and late apoptotic cells are in the lower right corner and upper right corner (double positive), respectively.
Necrotic cells lacking a cell membrane structure are in the upper left corner (PI positive). The numbers in the ﬁgure represent the percentage
of the total cell population. (b) The histogram represents percentages of cell population (viable, early apoptotic, late apoptotic, and necrotic
cells) in diﬀerent series of TUNEL assay. Value represents mean ± SE (n = 3). Signiﬁcant diﬀerences between EEPS and NEEPS are indicated
by ∗(P<. 05) and ∗∗∗(P<. 001).
analysis was made by labeling with Br-dUTP following the
method of Darzynkiewicz et al. [19]. Brieﬂy, 1-2 × 106
cells were suspended in 0.5mL PBS. This suspension was
transferred with a Pasteur pipette into a 5mL polypropylene
tube containing 4.5mL of ice cold 1% formaldehyde in
PBS. The tube was kept for 15 minutes on ice. The cells
were centrifuged at 1200g for 5 minutes; cell pellet was
resuspended in 5mL of PBS and was centrifuged again. The
cell pellet was dissolved in 0.5mL of PBS. The suspension
was transferred with the help of Pasteur pipette to a tube
containing 4.5mL of ice-cold 70% ethanol. The cells were
centrifugedat1200gfor3minutesandethanolwasremoved.6 Evidence-Based Complementary and Alternative Medicine
94.13 61.25 50.16
56.76 44.77
1.6 1.9
2.4
0.3
18.69
19.76
0.8
21.55
27.49
0.39
20.12
22.13
0.5
23.37
31.36
100
101
102
103
104
F
L
2
-
H
P
I
i
n
t
e
n
s
i
t
y
100 101 102 103 104
FL1-H
(i) Control
100
101
102
103
104
F
L
2
-
H
100 101 102 103 104
FL1-H
(ii) EEPS (100μg)
100
101
102
103
104
F
L
2
-
H
100 101 102 103 104
FL1-H
(iii) EEPS (200μg)
100
101
102
103
104
F
L
2
-
H
P
I
i
n
t
e
n
s
i
t
y
FITC intensity FITC intensity
100 101 102 103 104
FL1-H
(iv) NEEPS (100μg)
100
101
102
103
104
F
L
2
-
H
100 101 102 103 104
FL1-H
(v) NEEPS (200μg)
(a)
0
20
40
60
80
100
120
P
o
p
u
l
a
t
i
o
n
c
e
l
l
(
%
)
Nano control EEPS (100μg) EEPS (200μg) NEEPS (100μg) NEEPS (200μg)
∗
∗
∗
∗
∗
∗∗
∗∗
Viable cells
Early apoptotic cells
Late apoptotic cells
Necrotic cells
(b)
Figure 6: (a) EEPS and NEEPS induced apoptosis in A549 cells. Cells were harvested and stained with Annexin V-FITC and propidium
iodide (PI). Ten thousand events were collected and analysed for each sample. (i) Control, (ii)-(iii) Cells treated with two doses of EEPS (100
and 200μg), and (iv)-(v) Cells treated with two doses of NEEPS (100 and 200μg). (b) Histogram represents percentages of cell population
(viable, early apoptotic, late apoptotic, and necrotic cells) in diﬀerent series by Annexin V-FITC assay. Values represent mean ± SE (n = 3).
Signiﬁcant diﬀerences between EEPS and NEEPS are indicated by ∗(P<. 05) and ∗∗(P<. 01).
Then, the cells were resuspended in 5mL of PBS and were
centrifuged again at 1200g for 5 minutes. The pellet was
ﬁnally suspended in 50μl of a solution containing: 10μl
TdT 5X reaction buﬀer, 2.0μl of Br-dUTP stock solution
(0.5μl (12.5U) TdT, 5μlC o C l 2 solution, and 33.5μl distilled
H2O. Next, the cells were incubated in this solution for 40
minutes at 37◦C; 1.5mL of the rinsing buﬀer was added,
and then centrifuged at 1200g for 5 minutes. The cell pellet
was resuspended in 100μl of FITC- (or Alexa Fluor 488)
conjugated anti-Br-dU mAb solution procured from Abcam
USA (1:1000). Then, the cells were incubated at room
temperature for 1 hour. 1mL of PI staining solution was
added. Finally, the cells were incubated for 30 minutes at
room temperature, or 20 minutes at 37◦C in the dark, and
after incubation were analyzed by ﬂow cytometry (Becton
Dickinson, CA, USA).
2.12. Double Labeling of Cells with Annexin V-FITC and
Propidium Iodide. Perturbation in the cellular membrane
occurs during the early stages of apoptosis that leads toEvidence-Based Complementary and Alternative Medicine 7
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Figure 7: Eﬀect of EEPS and its nanoparticle on A549. A549 cells
were treated with drugs for 24 hours. Genomic DNA was extracted
and DNA was separated on 1% agarose gels and stained with
Ethidium bromide. The ﬁrst lane contains a standard DNA ladder,
lane two contains DNA from untreated cells, lane three contains
DNA from EEPS (100μg), lane four contains DNA from EEPS
(200μg), lane ﬁve from nanoparticles (100μg), and lane six from
nanoparticles (200μg) of P. senega-treated cells.
a redistribution of phosphatidylserine to the external side
of the cell membrane. Annexin V selectively binds to phos-
phatidylserine and thus, enables the use of a ﬂuorescence-
labeled Annexin V to identify the cell undergoing apoptosis.
The cells were also stained with Propidium iodide to
distinguish early apoptotic cells from necrotic cells. 1 × 106
cellspersampleweretakenintosmallcentrifugetubes.Then,
the cells were spun at 1200g for 5 minutes and after that
supernatants were discarded and pellet was washed with
500μl binding buﬀer. The cells were harvested at 1200g for
5 minutes, and cell pellet was resuspended in 80μl binding
buﬀer. 10μl Annexin V-FITC and 10μl of Propidium iodide
labeling solutions were added, and the cell suspension was
incubated for 15 minutes at room temperature in the dark.
Then the solution was ready for analysis by ﬂow cytometry.
2.13.DNALaddering. Thecellswereharvestedafterdiﬀerent
treatments into extraction buﬀer (10mM Tris-HCl pH 7.4,
containing 10mM NaCl, 20mM EDTA, and 1% Triton
X-100) after 24 hours of treatment. Genomic DNA was
isolated by digesting the cell extract with 10μg/mL of
proteinase K at 56◦C for 8–12 hours. DNA was puriﬁed by
phenol/chloroform, precipitated with ethanol and dissolved
in Tris EDTA (TE). Integrity of DNA was analyzed by gel
electrophoresis on 1% agarose gels followed by Ethidium
bromide staining.
2.14. Hoechst 33258 Staining. To observe nuclear changes
occurring during apoptosis, the chromatin-speciﬁc dye
Hoechst 33258 was used [20]. Cultures were ﬁxed for 5
minutes with 4% formaldehyde in PBS at 37◦C and then
Table 1: Primer sequences of cancer-related genes (human origin)
used in this study.
Primer name Primer sequences
β-actin Catalogue number-117816,GeNei (purchased
from Bangalore GeNei)
Survivin F: ATGACGACCCCATGCAAA
R: AGGATTTAGGCCACTGCCTT
PCNA Catalogue number-117813,GeNei (purchased
from Bangalore GeNei
Caspase-3 F: AGGCGGTTGTAGAAGTTAATAAAGGT
R: AGCGACTGGATGAACCAGGA
p53 Catalogue number-117810,GeNei (purchased
from Bangalore GeNei)
permeabilized by treatment with a mixture of ethanol/acetic
acid (3:1) for 10 minutes at 25◦C. After being washed
with PBS, the cells were stained with 1μg/mL Hoechst
33258 in PBS for 10 minutes at room temperature and then
washed again. Apoptosis was determined morphologically
afterstainingthecellswithHoechst33258usingﬂuorescence
microscopy (Axiscope plus 2, Zeiss, Germany).
2.15. RNA Extraction and Quantitative Reverse Transcriptase-
Polymerase Chain Reaction (RT-PCR) Analysis. The total
RNA was extracted from the A549 cells using Trizol reagent
according to the manufacturer’s instructions. The RNA
concentration was determined spectrophotometrically at
260nm. The RNA was diluted to 2μg/mL with water
pretreated with diethylpyrocarbonate (DEPC), containing
1U/μl RNase inhibitor. The following ingredients were
placed into a tube: 1μlR N A ,1 μl oligo (dT) 18, 1μl
reverse transcriptase, 2μl 10mM deoxynucleoside triphos-
phate (dNTP), 4μl5 xb u ﬀer, and sterilized in distilled
w a t e ru pt oat o t a lv o l u m eo f2 0μl. Then, the mixture was
incubatedat37◦Cfor60minutes.Afterreversetranscription,
the sample was heated at 95◦C for 5 minutes to denature the
reverse transcriptase, and then stored at −20◦Cf o rP C R .
The synthetic oligonucleotide primers used for RT-PCR
(Table 1) were procured from Bangalore Genei, Bangalore,
India and Bioserve Biotechnologies India Pvt. Ltd. β-actin
was used as an internal standard to normalize all samples
for potential variations in mRNA content. Single-stranded
cDNA was used as template for PCR ampliﬁcation by using
Taq polymerase. After 5 minutes at 94◦C, ampliﬁcation was
performed for all samples under the following conditions:
94◦C for 30 seconds, 52◦C for 30 seconds, and 72◦Cf o r
30 seconds for 35 cycles, with a ﬁnal incubation at 72◦C
for 7 minutes. Following PCR, 5μl samples aliquots were
subjected to electrophoresis on 1% (w/v) agarose gel for 20–
30 minutes and then stained with Ethidium bromide and
photographed. The band density was measured using Ultra
Lum digital imaging Gel Documentation System (USA) and
analyzed by Total lab software (UK).
2.16. Statistical Analysis. Results were given as mean ±
SE. Diﬀerences between the data of EEPS and NEEPS8 Evidence-Based Complementary and Alternative Medicine
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Figure 8: Fluorescence photomicrographs of A549 cells with Hoechst 33258 staining. The assessment of nuclear morphology of the cell was
performed after A549 cells were incubated for 24 hours with vehicle, with EEPS and NEEPS. →: nuclear condensation.
were calculated for statistical signiﬁcance by following the
Student’s t-test method. P values less than .05 to .001 were
considered signiﬁcant.
3. Results
3.1. Characterization of PLGA-Encapsulated Drugs. The
morphology of PLGA-encapsulated drug under scanning
microscopy and atomic force microscopy with correspond-
ing3DimageisshowninFigures1(a)–1(c).PLGA-associated
drug nanoparticles had 80% encapsulation eﬃciency. SEM
was used to investigate the morphology of nanoparticles.
As showed in Figure 1(a), the nanoparticles displayed a
spherical shape. AFM image (Figures 1(b) and 1(c))o f
NEEPS show nanoparticle surface without any noticeable
pinholes or cracks. AFM also revealed that all nanoparticles
were spherical in shape and below 150nm in size.
3.2. Particle Size and Zeta-Potential Determination by DLS.
DLS data showed that the mean diameter of PLGA encap-
sulated nanoparticles was 147.7 ± 4nm with polydispersity
indexof0.273 ±0.012(Figure 2(a)).Thezetapotentialofthe
drug encapsulated form was −31.6 ± 2.5mV (Figure 2(b)).
The nanoparticles size, as observed by AFM, correlated
well with the size measured by DLS. Zeta potential of the
nanoparticles was negative due to the presence of terminal
carboxylic groups in the polymers. Miller [21] demonstrated
that a high potential value of about −25mV ensures a high-
energy barrier that stabilizes the nanosuspension. Here also,
PLGA particles seemed to possess the ideal surface charge,
−31.6mV for EEPS loaded nanoparticles.
3.3. Eﬀects on Cell Viability. To determine the eﬀects of
blank nanoparticles, EEPS, and NEEPS on cell viability, the
viability of the treated normal lung cells (Figure 3(a))a n d
A549 cells (Figure 3(b)) was measured by MTT assay. EEPS
and NEEPS did not show any cytotoxic eﬀect on normal
lung cell. As compared to exposure of A549 cells for 24
hours to blank nanoparticles, the exposure of the cells to
EEPS and NEEPS at diﬀerent doses (20, 40, 80, 100, 160,
and 200μg/mL) signiﬁcantly inhibited their viability (P<
.05, P<. 01, P<. 001) in a dose-dependent mannerEvidence-Based Complementary and Alternative Medicine 9
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Figure 9: mRNA expression of survivin, PCNA, caspase-3, p53
analyzed by RT-PCR in EEPS- and NEEPS-treated cells as well as
in control cells. β-actin was used as a loading control. Ln1-Control,
Ln2-EEPS(100μg),Ln3-EEPS(200μg),Ln4-NEEPS(100μg),and
Ln5- NEEPS (200μg).
(Figure 3(b)).Thegrowthofthecells(68.65%)wasinhibited
by the EEPS treatments at dose 200μg/mL. On the contrary,
NEEPS at same dose inhibited the growth by 77.46% in A549
cellsduringthetestingperiod.Theeﬀectwasrelativelystrong
in the NEEPS than in the EEPS.
3.4. EEPS Uptake in Cells by Fluorescence Method. To check
if the drug-loaded nanoparticles were internalized in cancer
cells, the cellular uptake of NEEPS was evaluated on A549
cells at diﬀerent time intervals. The data of the time taken
by the EEPS and NEEPS have been presented in Figure 4(a).
The data indicates that the rate of entry into the cells
startedincreasingafter30minutesonwardforNEEPSand45
minutes for EEPS. Therefore, NEEPS entered more rapidly
than EEPS. The cells became saturated after 240 minutes
in both capsulated and unencapsulated forms. In NEEPS-
treated series, the percentages of ﬂuorescence positive cells
were higher (P<. 05, P<. 01, P<. 001) as compared to
EEPS-treated series at diﬀerent time intervals (Figure 4(b)).
76.2%–80% of cells showed ﬂuorescence after 2-3hours of
incubation with NEEPS.
3.5. Apoptosis Assay by TUNEL Method Using FACS. To
investigate the eﬀects of EEPS and NEEPS on the induction
of apoptosis in A549 cells, ﬂow cytometric measurement
by TUNEL assay was used to quantify the percentages of
apoptosis in the total cell population. Results of the TUNEL
assay for determining the percentages of early and late
apoptotic cells have been furnished in Figures 5(a) and
5(b). The data revealed that the PLGA-encapsulated NEEPS
showed signiﬁcantly greater apoptotic activities (P<. 05, P<
.001) than their unencapsulated forms at doses of 100μga n d
200μg, respectively. The frequencies of early apoptotic cells
were 27% and 43.46% at 100 and 200μg doses, respectively,
for EEPS, while these were 32% and 48.15%, respectively, for
NEEPS. The late apoptotic cells in EEPS comprised 3.58%
and 10.84%, respectively, for 100 and 200μg, while in the
NEEPS, these were 7.5% and 16.78%, respectively.
3.6. Apoptosis Assay by Annexin V-FITC and PI Staining
Methods Using FACS. To further investigate these ﬁndings,
we performed Annexin V assay on A549 cell. Figures 6(a)
and 6(b) show that treatment of A549 cell line with EEPS
and NEEPS induces apoptosis. The FACS data of Annexin V-
FITC staining have been presented in Figures 6(a) and 6(b).
The data were in agreement with that of TUNEL assay using
FACS, in respect of both EEPS and NEEPS. Thus, results of
both TUNEL assay and Annexin V methods complemented
each other and reaﬃrmed the greater apoptotic potential
(P<. 05, P<. 01) of the PLGA-encapsulated nano
forms than their unencapsulated forms, which also showed
considerable apoptotic activities at the higher dose.
3.7. DNA Ladder Assay. During the course of the above
experiments, we noticed that many cells detached from the
surface of the cell culture plate, suggesting some form of cell
death. To investigate this, we treated A549 cells with 100μg
and 200μg of EEPS and NEEPS and then, extracted their
genomicDNAandanalyzeditonagarosegels.Figure 7shows
that the DNA from control cells was intact, while the DNA
from cells treated with EEPS and NEEPS exhibited a smear
corresponding to a laddering of DNA.
3.8. Hoechst 33258 Staining. Furthermore, we also observed
the morphologic changes of the nucleus by Hoechst 33258
staining. In the control group, the nuclei of the A549 cells
wereroundandhomogeneouslystained(Figure 8).However,
EEPS- and NEEPS-treated A549 cells showed granular
apoptotic bodies (nuclear condensation) (Figure 8). These
results demonstrate that NEEPS induces greater apoptosis of
A549 cells than EEPS.
3.9. RT-PCR Data of Some Key Signal Proteins. mRNA level
of caspase-3, survivin, PCNA, p53 in response to EEPS and
NEEPS treatment was evaluated (Figures 9 and 10). For
normalization of data, a house-keeping gene β-actin has also
been considered. Survivin, a member of the IAP family, is a
bifunctional protein that suppresses apoptosis and regulates
cell division. 24 hours after the treatment with EEPS, the
expression of survivin mRNA was detected by RT-PCR. The
statistical analysis showed that the expression of survivin
mRNA in A549 cells was down-regulated signiﬁcantly by
E E P Sa sc o m p a r e dw i t ht h ec o n t r o l( F i g u r e s9 and 10,
Table 2). PCNA is usually regarded as a proliferation marker.
Decreased expression upon drug treatment revealed the
antiproliferative eﬀect of EEPS and NEEPS. p53 has several10 Evidence-Based Complementary and Alternative Medicine
3.42
3.44
3.46
3.48
3.5
3.52
3.54
3.56
B
a
n
d
d
e
n
s
i
t
y
β -actin
Ln1 Ln2 Ln3 Ln4 Ln5
0
1
2
3
4
5
6
7
8
9
B
a
n
d
d
e
n
s
i
t
y
Survivin
Ln1 Ln2 Ln3 Ln4 Ln5
∗
∗
0
1
2
3
4
5
6
7
8
9
10
B
a
n
d
d
e
n
s
i
t
y
PCNA
Ln1 Ln2 Ln3 Ln4 Ln5
∗∗
∗∗
0
2
4
6
8
10
12
14
16
18
B
a
n
d
d
e
n
s
i
t
y
Caspase-3
Ln1 Ln2 Ln3 Ln4 Ln5
∗
∗∗
0
2
4
6
8
10
12
14
B
a
n
d
d
e
n
s
i
t
y
P53
Ln1 Ln2 Ln3 Ln4 Ln5
∗
∗∗∗
Figure 10: Histogram represents data of band density of diﬀerent mRNA expressions in EEPS- and NEEPS-treated cells along with control
cells. ∗, ∗∗,a n d∗∗∗ denote signiﬁcant diﬀerences (P<. 05 and P<. 01, P<. 001, resp.) between EEPS and NEEPS for both doses. Ln1-
Control, Ln2- EEPS (100μg), Ln3- EEPS (200μg), Ln4- NEEPS (100μg), and Ln5- NEEPS (200μg). Band density was expressed as a mean
± SE of the three independent experiments.
Table 2:BanddensityofdiﬀerentmRNAexpressionsindiﬀerentseries.Banddensitywasexpressedasamean ±SEofthethreeindependent
experiments. Signiﬁcant diﬀerences between EEPS and NEEPS are indicated by ∗(P<. 05), ∗∗(P<. 01) and ∗∗∗(P<. 001).
Signalling molecule Band density
Ln1 (Control) Ln2 (EEPS 100μg) Ln3 (EEPS 200μg) Ln4 (NEEPS 100μg) Ln5 (NEEPS 200μg)
β-actin 3.52 ±0.015 3.54 ±0.035 3.5 ±0.052 3.48 ±0.032 3.52 ±0.028
Survivin 7.6 ±0.21 6.8 ±0.125 5.8 ±0.32 6.15 ±0.185
∗ 4.2 ±0.15
∗
PCNA 8.25 ±0.15 7.5 ±0.12 6.25 ± 0.25 6.58 ±0.15
∗∗ 4.85 ±0.125
∗∗
Caspase-3 9.21 ±0.13 11.5 ±0.18 13.52 ±0.15 12.42 ±0.12
∗ 15.4 ±0.35
∗∗
p53 6.8 ±0.74 7.2 ±0.32 9.25 ± 0.15 8.85 ±0.4
∗ 11.52 ±0.16
∗∗∗
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Figure 11: A schematic diagram of possible molecular events in
EEPS/NEEPS-induced apoptosis of cancer cell (A549).
target genes and it is quite well established that p53 plays an
important role in cell cycle arrest and in apoptosis. The RT-
PCR studies revealed signiﬁcant overexpression of mRNA of
p53 in EEPS- and NEEPS-administered groups, as compared
to control (Figures 9 and 10). Caspases, the cytoplasmic
aspartate-speciﬁccysteineproteases,havebeenshowntoplay
acentralroleintheapoptoticsignalingpathway.Caspase-3,a
member of the caspase family, was shown to play an essential
role in apoptosis induced by a variety of stimuli. Finally,
we examined whether caspase-3 expression was increased
during EEPS-induced apoptosis in A549 cells. On further
critical analysis of the data between EEPS and NEEPS, we
found that the latter showed stronger eﬀect (P<. 05, P<. 01,
P<. 001).
4. Discussion
TheaboveresultsrevealthattheNEEPSshowedconsiderable
inhibitory activity on cellular growth, more by apoptosis
thanbynecrosisintheA549cells;butinterestingly,EEPSand
NEEPSdidnothavemuchcytotoxicitywhenadministeredto
normal lung cells in culture. Thus, both appeared to have an
aﬃnity of targeting the cancer cells and to kill them, while
leaving the normal cells less aﬀected. The principal active
constituents of P. senega are saponin glycosides polygalicacid
and senegin, which make up 5% and 4%, respectively, of
the dried root [22]. Earlier studies have revealed P. senega
to be immunostimulating but not tumoricidal [23, 24]. The
ﬁndings of the present paper would suggest that they also
have considerable anticancer potentials against lung cancer
cells.
However, the anticancer eﬀect of any individual ingredi-
ent of the root extract has not yet been studied and may form
the basis for future studies. Therefore, till such studies are
conducted, the collective eﬀect of all the ingredients in the
root extract could currently be attributed for the anticancer
potentials of EEPS. Further, the result of the present paper
would reveal that the nanoencapsulation made the extract
more potent as an anticancer agent. This could possibly
be because it rendered the extract more water soluble and
easy to enter the cell bringing with it the anticancer agent
inside the cancer cell only to facilitate the cancer cell’s death.
In the current paper, we consciously used biodegradable
nanoparticles formulation of plant extract based on poly
(lactide-co-glycolide) technique using a stabilizer (Pluronic
F-68),andtesteditsbioavailabilityandeﬀectsoncellgrowth.
Although this approach has been used to encapsulate a wide
variety of hydrophobic drugs including natural products
such as curcumin [25, 26], coenzyme Q10 [27], and estradiol
[28], to the best of our knowledge, only another plant extract
(Gelsemium sempervirens) that is used as a homeopathic
mother tincture has so far been successfully encapsulated by
this method [9].Ontreatmentofaqueoussolutions ofPLGA
with root extract, rapid formation of PLGA nanoparticles
takes place at high concentrations and these are quite stable
in nature.
On the other hand, the use of metal nanoparticles has
been made more frequently for various purposes. There
are many reports in the literature on the biogenesis of
silver nanoparticles using several plant extracts, particularly
Neem leaf broth (Azadirachta indica) and geranium leaves
(P. graveolens)[ 29, 30]. However, the synthesis of PLGA
nanoparticles using plant extract has not yet been studied
for a large number of natural compounds. The results
of the present paper suggested that the higher dose was
more eﬃcient in inducing apoptosis as compared to the
lower dose. Quantitative determination of apoptotic cells
by TUNEL assay, Annexin V-FITC labeling method also
indicated that NEEPS exhibited relatively higher inductive
activityonapoptosisofA549cellsthanEEPS.Theexpression
of survivin is highly cancer-speciﬁc and is one of the top
four transcripts uniformly up-regulated in human cancers,
but not in the normal tissues [31]. The overexpression of
survivin appears to correlate with aggressive tumor behavior
and poor prognosis in nonsmall cell lung cancers [32]a n d
hepatocellular carcinoma [33]. This ﬁnding also demon-
strates that the apoptosis of A549 cells by EEPS and NEEPS
is associated with the down-regulation of survivin, PCNA
mRNA expression. Caspase-3, the ultimate executioner that
is essential for the nuclear changes, associated with apoptosis
[20]. In the present paper, we found that the EEPS and
NEEPS-induced apoptosis of A549 was also related to the
overexpression of caspase-3 and p53 (Figures 9 and 10).
The molecular apoptotic pathway of NEEPS/EEPS-treated
cells was found to be induced by activation of caspase-3
and p53 and suppression of survivin and PCNA expression.
The entire process may be schematically represented as
shown in Figure 11. Therefore, in our present formulation
using a biodegradable nanoparticles-encapsulation of EEPS
with PLGA, we were able to increase the bioavailability
and thereby improve its overall inhibitory eﬀects on cell
proliferation.
Epidemiological data support the concept that naturally
occurring anticancer agents in the human diet are safe, and12 Evidence-Based Complementary and Alternative Medicine
nontoxic, and they have long lasting beneﬁcial eﬀects on
human health [34, 35]. Therefore, P. senega and its nanoen-
capsulatedformcanbeusedasasafedietarysupplementthat
may act as a chemopreventive agent against lung cancer.
5. Conclusion
In conclusion, it has been demonstrated that homeopathic
mother tincture of P. senega has an anticancer eﬀect against
lung cancer cells in vitro, and PLGA encapsulation helps
it to enhance its cellular uptake and anticancer poten-
tials, presumably by increasing drug bioavailability. This
should stimulate further research on nano-encapsulation
of homeopathic mother tinctures, as also medicinal herbal
extracts, particularly with suspected anticancer potentials, to
examinewhetherthiswouldprovetobea novel approachfor
accelerating anticancer potentials for other cases as well.
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